← Listen againIn Conversation
Health Explained: A New Generic HIV Prevention Injection November 4, 2026 · 3:32 · With Maya and Grace
We share health news in clear English, so you can understand what is happening and why it matters. Grace is our columnist for health and medicine. Thanks for listening. Grace,…
Transcript Maya Welcome to Slow English FM and Health Explained. I’m Maya. We share health news in clear English, so you can understand what is happening and why it matters. Grace is our columnist for health and medicine. Thanks for listening. Maya Grace, the U.S. Food and Drug Administration, or FDA, has given Dr. Reddy’s tentative approval for a generic version of lenacapavir. What does that mean for HIV prevention? Grace Lenacapavir is a long-acting injection used to help prevent HIV. It is given twice a year, rather than taken as a pill every day. The FDA granted tentative approval, a key step toward access to a generic version. Maya What still needs to happen before people can get it? Grace The Business Standard reports that wider availability also depends on World Health Organization prequalification and approval by regulators in each country. Prequalification is a review that helps health programs assess whether a medicine meets standards for use. Maya The expected price is $40 per person each year. Who is that price meant for, and what is the basis for it? Grace Under an agreement with Unitaid, Wits RHI, and the Clinton Health Access Initiative, the generic is expected to cost $40 per person per year in 120 countries covered by Gilead’s voluntary license. A voluntary license allows another company to make a generic version under agreed terms. Maya And what is the expected timeline for supplies? Grace Dr. Reddy’s says initial supplies are expected to reach countries before the end of 2026, with wider rollout in eligible markets in 2027. The wider rollout still depends on the remaining approvals and country introduction steps. Maya How did this generic reach tentative approval so soon after the original product? Grace Gilead granted Dr. Reddy’s a voluntary license in October 2024. Then, in September 2025, Dr. Reddy’s agreed to work with Unitaid, Wits RHI, and CHAI on development, regulatory progress, and affordable access. CHAI says financial, technical, and regulatory support helped speed the work. The company received tentative FDA approval about 16 months after the original product was approved for prevention, according to CHAI. Maya A shot twice a year could be easier for some people than taking a pill every day. What else has to be in place for that option to reach people? Grace Wits RHI says an affordable medicine alone is not enough. Health services need to be ready to provide it, health workers need training, and communities need to be involved. The medicine has to reach people through local health systems. Maya So this is an important approval, but access will depend on price, remaining approvals, and how well countries prepare to deliver the injections. Grace, thank you for explaining it. Grace Thank you, Maya. Maya You’ve been listening to Health Explained on Slow English FM. Thanks for being with us.
